Last reviewed · How we verify
Enoxaparine infusion
Enoxaparine infusion is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome. Also known as: ARIXTRA infusion.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | Enoxaparine infusion |
|---|---|
| Also known as | ARIXTRA infusion |
| Sponsor | GlaxoSmithKline |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Coagulation factors Xa and IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The low-molecular-weight formulation provides more predictable pharmacokinetics and predominantly anti-Xa activity compared to unfractionated heparin.
Approved indications
- Thromboembolism prophylaxis in surgical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
- Prevention of thromboembolic complications in atrial fibrillation
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE2)
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants (PHASE2)
- Strategies for Anticoagulation During Venovenous ECMO (NA)
- Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
- Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (PHASE2)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (PHASE4)
- Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparine infusion CI brief — competitive landscape report
- Enoxaparine infusion updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Enoxaparine infusion
What is Enoxaparine infusion?
How does Enoxaparine infusion work?
What is Enoxaparine infusion used for?
Who makes Enoxaparine infusion?
Is Enoxaparine infusion also known as anything else?
What drug class is Enoxaparine infusion in?
What development phase is Enoxaparine infusion in?
What are the side effects of Enoxaparine infusion?
What does Enoxaparine infusion target?
Related
- Drug class: All Low-molecular-weight heparin (LMWH) drugs
- Target: All drugs targeting Coagulation factors Xa and IIa (via antithrombin III enhancement)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thromboembolism prophylaxis in surgical patients
- Indication: Drugs for Treatment of deep vein thrombosis and pulmonary embolism
- Indication: Drugs for Acute coronary syndrome
- Also known as: ARIXTRA infusion
- Compare: Enoxaparine infusion vs similar drugs
- Pricing: Enoxaparine infusion cost, discount & access